Xuan Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xuan Zhang has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Abbas K. Samadi
Department of Surgery, University of Kansas Medical Center, Kansas City, KS, USA
2 shared publications Barbara Timmermann
Department of Medicinal Chemistry, The University of Kansas, Lawrence, KS 66045, USA
2 shared publications- Fabian D'SOuza
Boston Strategic Partners, Inc, Boston, USA
2 shared publications - Mark S. Cohen
Department of Surgery, University of Kansas Medical Center, Kansas City, KS
2 shared publications Abbas K. Samadi
Department of Surgery, University of Kansas School of Medicine, Kansas City, KS 66160, USA
1 shared publication- Andrew D. Shaw
Department of Intensive Care and Resuscitation, Cleveland Clinic, Cleveland, Ohio, USA
1 shared publication
Latest Publications
- Open Access
- 29 September 2025
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (10)
Albumin prevents kidney injury but is underutilized in a cohort of patients undergoing large-volume paracentesis
Background: Cirrhosis and cirrhosis-related deaths have risen in the United States in recent years. Ascites is a common complication, often requiring large-volume paracentesis (LVP). The American Association for the Study of Liver Diseases (AASLD) recommends the administration of albumin in conjunction with LVP to prevent further complications of cirrhosis. Emerging research in cirrhosis care reveals significant variations in outcomes among different demographics. Therefore, we assessed the use of guideline-adherent albumin and outcomes in U.S. patients undergoing LVPs, particularly at the intersection of race, ethnicity, socioeconomic disparities, and cirrhosis. Methods: This retrospective study utilized Cerner Real World Data to identify adults with cirrhosis and ascites undergoing LVP between January 2016 and June 2022. We assessed albumin utilization patterns across racial and ethnic groups and payor types, and their overall impact on acute kidney injury (AKI)-related hospitalization using an adjusted generalized linear model (aGLM). Results: We identified 736 patients: 301 in the LVP + albumin group and 435 in the LVP-only group. Despite clinical recommendations, only 41% undergoing LVPs received albumin. White patients and commercially insured patients received albumin at higher rates (p=0.042 and p=0.009, respectively). The overall rate of AKI-related admissions within the 30-day post-procedure period was 26%. However, patients who received albumin during LVP had a 36% lower risk of short-term AKI-related hospitalization (OR: 0.64; p=0.03). Conclusions: These findings indicate a potential for broader albumin utilization in U.S. patients with refractory ascites undergoing repeated LVPs to reduce AKI-related admissions.
- 29 September 2025
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (10)
Open AccessAlbumin prevents kidney injury but is underutilized in a cohort of patients undergoing large-volume paracentesis
Background: Cirrhosis and cirrhosis-related deaths have risen in the United States in recent years. Ascites is a common complication, often requiring large-volume paracentesis (LVP). The American Association for the Study of Liver Diseases (AASLD) recommends the administration of albumin in conjunction with LVP to prevent further complications of cirrhosis. Emerging research in cirrhosis care reveals significant variations in outcomes among different demographics. Therefore, we assessed the use of guideline-adherent albumin and outcomes in U.S. patients undergoing LVPs, particularly at the intersection of race, ethnicity, socioeconomic disparities, and cirrhosis. Methods: This retrospective study utilized Cerner Real World Data to identify adults with cirrhosis and ascites undergoing LVP between January 2016 and June 2022. We assessed albumin utilization patterns across racial and ethnic groups and payor types, and their overall impact on acute kidney injury (AKI)-related hospitalization using an adjusted generalized linear model (aGLM). Results: We identified 736 patients: 301 in the LVP + albumin group and 435 in the LVP-only group. Despite clinical recommendations, only 41% undergoing LVPs received albumin. White patients and commercially insured patients received albumin at higher rates (p=0.042 and p=0.009, respectively). The overall rate of AKI-related admissions within the 30-day post-procedure period was 26%. However, patients who received albumin during LVP had a 36% lower risk of short-term AKI-related hospitalization (OR: 0.64; p=0.03). Conclusions: These findings indicate a potential for broader albumin utilization in U.S. patients with refractory ascites undergoing repeated LVPs to reduce AKI-related admissions.
- Open Access
- 7 November 2024
- Published by Springer Nature in Discover Public Health
- Vol. 21 (1) , 1-20
Machine learning insights into regional dynamics and prevalence of COVID-19 variants in US health and human services regions
- 7 November 2024
- Published by Springer Nature in Discover Public Health
- Vol. 21 (1) , 1-20
Open AccessMachine learning insights into regional dynamics and prevalence of COVID-19 variants in US health and human services regions
- Open Access
- 26 October 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Access
- Vol. 11, 123445-123457
The Economic Value and Clinical Impact of Artificial Intelligence in Healthcare: A Scoping Literature Review
Artificial Intelligence (AI)-supported healthcare has seen a substantial rise in development in recent years. The health economic impact is a crucial factor in the decision-making process regarding AI adoption. This study aimed to analyze the latest research progress and evidence on the cost-effectiveness and clinical efficiency of healthcare AI software from various perspectives, as well as to identify future opportunities and remaining challenges. A review of global literature was conducted using two key databases, PubMed and Embase, along with other related bibliographic resources. The literature search yielded 1,178 unique articles, of which 31 were included in our analysis. These studies covered a wide variety of clinical use cases and healthcare domains, including disease diagnosis (n=13, 41.9%), risk analysis (n=6, 19.4%), screening or patient triage (n=6, 19.4%), treatment delivery (n=5, 16.1%), and patient engagement or follow-up (n=1, 3.2%). Among the included studies, 24 (77.4%) examined the cost-effectiveness of AI compared to standard human-based practices from the perspectives of patients, healthcare systems, payors, or society. The remaining 7 studies, including 5 clinical trials, concluded that AI can enhance the clinical efficiency by shortening labor time or patient journey in the clinic. The findings of this targeted literature review demonstrated that leveraging AI in human decision-making has the potential to improve multilevel health outcomes. However, there is a shortage of prospective health economic studies, particularly long-term evaluations, highlighting the disparity between the rapid progress of AI and its lagging utilization in real-world practices.
- 26 October 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Access
- Vol. 11, 123445-123457
Open AccessThe Economic Value and Clinical Impact of Artificial Intelligence in Healthcare: A Scoping Literature Review
Artificial Intelligence (AI)-supported healthcare has seen a substantial rise in development in recent years. The health economic impact is a crucial factor in the decision-making process regarding AI adoption. This study aimed to analyze the latest research progress and evidence on the cost-effectiveness and clinical efficiency of healthcare AI software from various perspectives, as well as to identify future opportunities and remaining challenges. A review of global literature was conducted using two key databases, PubMed and Embase, along with other related bibliographic resources. The literature search yielded 1,178 unique articles, of which 31 were included in our analysis. These studies covered a wide variety of clinical use cases and healthcare domains, including disease diagnosis (n=13, 41.9%), risk analysis (n=6, 19.4%), screening or patient triage (n=6, 19.4%), treatment delivery (n=5, 16.1%), and patient engagement or follow-up (n=1, 3.2%). Among the included studies, 24 (77.4%) examined the cost-effectiveness of AI compared to standard human-based practices from the perspectives of patients, healthcare systems, payors, or society. The remaining 7 studies, including 5 clinical trials, concluded that AI can enhance the clinical efficiency by shortening labor time or patient journey in the clinic. The findings of this targeted literature review demonstrated that leveraging AI in human decision-making has the potential to improve multilevel health outcomes. However, there is a shortage of prospective health economic studies, particularly long-term evaluations, highlighting the disparity between the rapid progress of AI and its lagging utilization in real-world practices.
- 8 June 2020
- Published by Taylor & Francis in Journal of Biopharmaceutical Statistics
- Vol. 30 (5) , 916-940
Measuring individual benefits of psychiatric treatment using longitudinal binary outcomes: Application to antipsychotic benefits in non-cannabis and cannabis users
We present and evaluate a method for predicting individual treatment benefits based on random effects logistic regression models of binary outcomes that change over time. The method uses empirical Bayes predictors based on patients’ characteristics and responses to treatment. It is applicable to both 1-dimentional and 2-dimentional personalized medicine models. Comparisons between predicted and true benefits for simulated new patients using correlations, relative biases and mean-squared errors were used to evaluate prediction performance. The predicted benefits had relatively small biases and relatively high correlations with the true benefits in the simulated new patients. The predictors also captured estimated overall population trends in the evolution of individual benefits. The proposed approach can be used to retrospectively evaluate patients’ responses in a clinical trial, or to retrospectively or prospectively predict individual benefits of different treatments for new patients using patients’ characteristics and previous responses. The method is used to examine changes in the disorganized dimension of antipsychotic-naïve patients from an antipsychotic randomized clinical trial. Retrospective prediction of individual benefits revealed that more cannabis users had slower and lower responses to antipsychotic treatment as compared to non-cannabis users, revealing cannabis use as a negative prognostic factor for psychotic disorders in the disorganized dimension.
- 8 June 2020
- Published by Taylor & Francis in Journal of Biopharmaceutical Statistics
- Vol. 30 (5) , 916-940
Measuring individual benefits of psychiatric treatment using longitudinal binary outcomes: Application to antipsychotic benefits in non-cannabis and cannabis users
We present and evaluate a method for predicting individual treatment benefits based on random effects logistic regression models of binary outcomes that change over time. The method uses empirical Bayes predictors based on patients’ characteristics and responses to treatment. It is applicable to both 1-dimentional and 2-dimentional personalized medicine models. Comparisons between predicted and true benefits for simulated new patients using correlations, relative biases and mean-squared errors were used to evaluate prediction performance. The predicted benefits had relatively small biases and relatively high correlations with the true benefits in the simulated new patients. The predictors also captured estimated overall population trends in the evolution of individual benefits. The proposed approach can be used to retrospectively evaluate patients’ responses in a clinical trial, or to retrospectively or prospectively predict individual benefits of different treatments for new patients using patients’ characteristics and previous responses. The method is used to examine changes in the disorganized dimension of antipsychotic-naïve patients from an antipsychotic randomized clinical trial. Retrospective prediction of individual benefits revealed that more cannabis users had slower and lower responses to antipsychotic treatment as compared to non-cannabis users, revealing cannabis use as a negative prognostic factor for psychotic disorders in the disorganized dimension.
- Open Access
- 25 October 2018
- Published by Springer Nature in Perioperative Medicine
- Vol. 7 (1) , 24
Pulmonary artery catheter use in adult patients undergoing cardiac surgery: a retrospective, cohort study
The utility of pulmonary artery catheters (PACs) and their measurements depend on a variety of factors including data interpretation and personnel training. This US multi-center, retrospective electronic health record (EHR) database analysis was performed to identify associations between PAC use in adult cardiac surgeries and effects on subsequent clinical outcomes. This cohort analysis utilized the Cerner Health Facts database to examine patients undergoing isolated coronary artery bypass graft (CABG), isolated valve surgery, aortic surgery, other complex non-valvular and multi-cardiac procedures, and/or heart transplant from January 1, 2011, to June 30, 2015. A total of 6844 adults in two cohorts, each with 3422 patients who underwent a qualifying cardiac procedure with or without the use of a PAC for monitoring purposes, were included. Patients were matched 1:1 using a propensity score based upon the date and type of surgery, hospital demographics, modified European System for Cardiac Operative Risk Evaluation (EuroSCORE II), and patient characteristics. Primary outcomes of 30-day in-hospital mortality, length of stay, cardiopulmonary morbidity, and infectious morbidity were analyzed after risk adjustment for acute physiology score. There was no difference in the 30-day in-hospital mortality rate between treatment groups (OR, 1.17; 95% CI, 0.65–2.10; p = 0.516). PAC use was associated with a decreased length of stay (9.39 days without a PAC vs. 8.56 days with PAC; p < 0.001), a decreased cardiopulmonary morbidity (OR, 0.87; 95% CI, 0.79–0.96; p < 0.001), and an increased infectious morbidity (OR, 1.28; 95% CI, 1.10–1.49; p < 0.001). Use of a PAC during adult cardiac surgery is associated with decreased length of stay, reduced cardiopulmonary morbidity, and increased infectious morbidity but no increase in the 30-day in-hospital mortality. This suggests an overall potential benefit associated with PAC-based monitoring in this population. The study was registered at clinicaltrials.gov (NCT02964026) on November 15, 2016.
- 25 October 2018
- Published by Springer Nature in Perioperative Medicine
- Vol. 7 (1) , 24
Open AccessPulmonary artery catheter use in adult patients undergoing cardiac surgery: a retrospective, cohort study
The utility of pulmonary artery catheters (PACs) and their measurements depend on a variety of factors including data interpretation and personnel training. This US multi-center, retrospective electronic health record (EHR) database analysis was performed to identify associations between PAC use in adult cardiac surgeries and effects on subsequent clinical outcomes. This cohort analysis utilized the Cerner Health Facts database to examine patients undergoing isolated coronary artery bypass graft (CABG), isolated valve surgery, aortic surgery, other complex non-valvular and multi-cardiac procedures, and/or heart transplant from January 1, 2011, to June 30, 2015. A total of 6844 adults in two cohorts, each with 3422 patients who underwent a qualifying cardiac procedure with or without the use of a PAC for monitoring purposes, were included. Patients were matched 1:1 using a propensity score based upon the date and type of surgery, hospital demographics, modified European System for Cardiac Operative Risk Evaluation (EuroSCORE II), and patient characteristics. Primary outcomes of 30-day in-hospital mortality, length of stay, cardiopulmonary morbidity, and infectious morbidity were analyzed after risk adjustment for acute physiology score. There was no difference in the 30-day in-hospital mortality rate between treatment groups (OR, 1.17; 95% CI, 0.65–2.10; p = 0.516). PAC use was associated with a decreased length of stay (9.39 days without a PAC vs. 8.56 days with PAC; p < 0.001), a decreased cardiopulmonary morbidity (OR, 0.87; 95% CI, 0.79–0.96; p < 0.001), and an increased infectious morbidity (OR, 1.28; 95% CI, 1.10–1.49; p < 0.001). Use of a PAC during adult cardiac surgery is associated with decreased length of stay, reduced cardiopulmonary morbidity, and increased infectious morbidity but no increase in the 30-day in-hospital mortality. This suggests an overall potential benefit associated with PAC-based monitoring in this population. The study was registered at clinicaltrials.gov (NCT02964026) on November 15, 2016.
- Open Access
- 30 November 2014
- Published by Impact Journals, LLC in Oncotarget
- Vol. 5 (22) , 11365-11380
Targeting of mutant p53-induced FoxM1 with thiostrepton induces cytotoxicity and enhances carboplatin sensitivity in cancer cells
Targeting of mutant p53-induced FoxM1 with thiostrepton induces cytotoxicity and enhances carboplatin sensitivity in cancer cells Targeting of mutant p53-induced FoxM1 with thiostrepton induces cytotoxicity and enhances carboplatin sensitivity in cancer cells
- 30 November 2014
- Published by Impact Journals, LLC in Oncotarget
- Vol. 5 (22) , 11365-11380
Open AccessTargeting of mutant p53-induced FoxM1 with thiostrepton induces cytotoxicity and enhances carboplatin sensitivity in cancer cells
Targeting of mutant p53-induced FoxM1 with thiostrepton induces cytotoxicity and enhances carboplatin sensitivity in cancer cells Targeting of mutant p53-induced FoxM1 with thiostrepton induces cytotoxicity and enhances carboplatin sensitivity in cancer cells
- Open Access
- 2 September 2012
- Published by Wiley in ISRN Biochemistry
- Vol. 2012, 1-6
Withaferin A Induces Proteasome-Dependent Degradation of Breast Cancer Susceptibility Gene 1 and Heat Shock Factor 1 Proteins in Breast Cancer Cells
The purpose of this study was to examine the regulation of prosurvival factors heat shock factor 1 (HSF1) and breast cancer susceptibility gene 1 (BRCA1) by a natural withanolide withaferin A (WA) in triple negative breast cancer cell lines MDA-MB-231 and BT20. Western analysis was used to examine alternations in HSF1 and BRCA1 protein levels following WA treatment. A protein synthesis inhibitor cycloheximide and a proteasome inhibitor MG132 were used to investigate the mechanisms of HSF1 and BRCA1 regulation by WA. It was found that WA induced a dose-dependent decrease in HSF1 and BRCA1 protein levels. Further analysis showed that levels of HSF1 and BRCA1 proteins decreased rapidly after WA treatment, and this was attributed to WA-induced denaturation of HSF1 and BRCA1 proteins and subsequent degradation via proteasome-dependent, and protein-synthesis dependent mechanism. In summary, WA induces denaturation and proteasomal degradation of HSF1 and BRCA1 proteins. Further studies are warranted to examine the contribution of HSF1 and BRCA1 depletion to the anticancer effects of WA in breast cancer.
- 2 September 2012
- Published by Wiley in ISRN Biochemistry
- Vol. 2012, 1-6
Open AccessWithaferin A Induces Proteasome-Dependent Degradation of Breast Cancer Susceptibility Gene 1 and Heat Shock Factor 1 Proteins in Breast Cancer Cells
The purpose of this study was to examine the regulation of prosurvival factors heat shock factor 1 (HSF1) and breast cancer susceptibility gene 1 (BRCA1) by a natural withanolide withaferin A (WA) in triple negative breast cancer cell lines MDA-MB-231 and BT20. Western analysis was used to examine alternations in HSF1 and BRCA1 protein levels following WA treatment. A protein synthesis inhibitor cycloheximide and a proteasome inhibitor MG132 were used to investigate the mechanisms of HSF1 and BRCA1 regulation by WA. It was found that WA induced a dose-dependent decrease in HSF1 and BRCA1 protein levels. Further analysis showed that levels of HSF1 and BRCA1 proteins decreased rapidly after WA treatment, and this was attributed to WA-induced denaturation of HSF1 and BRCA1 proteins and subsequent degradation via proteasome-dependent, and protein-synthesis dependent mechanism. In summary, WA induces denaturation and proteasomal degradation of HSF1 and BRCA1 proteins. Further studies are warranted to examine the contribution of HSF1 and BRCA1 depletion to the anticancer effects of WA in breast cancer.
- 1 March 2012
- Published by Elsevier in Gynecologic Oncology
- Vol. 124 (3) , 606-612
Inhibition of cell growth and induction of apoptosis in ovarian carcinoma cell lines CaOV3 and SKOV3 by natural withanolide Withaferin A
- 1 March 2012
- Published by Elsevier in Gynecologic Oncology
- Vol. 124 (3) , 606-612
Inhibition of cell growth and induction of apoptosis in ovarian carcinoma cell lines CaOV3 and SKOV3 by natural withanolide Withaferin A
- 1 February 2012
- Published by Springer Nature in Endocrine
- Vol. 42 (1) , 97-106
Estrogen suppresses expression of the matrix metalloproteinase inhibitor reversion-inducing cysteine-rich protein with Kazal motifs (RECK) within the mouse uterus
RECK (reversion-inducing cysteine-rich protein with Kazal motifs) is a membrane-anchored glycoprotein which regulates MMP2 and MMP9 activity and has been proposed to play a role in embryo implantation while misexpression of RECK has been associated with a variety of carcinomas. Unfortunately, understanding on the steroidal regulation of uterine RECK is lacking. To address this gap in our knowledge, we examined steroidal regulation and cellular expression of Reck mRNA and protein within the mouse uterus in vivo. Uterine Reck mRNA and protein were decreased by estrogen, while progesterone alone had no effect. The estrogen-induced down regulation could be partially blocked by progesterone. RECK was localized primarily to luminal and glandular epithelial cells and the level of expression was regulated in a similar fashion as in whole tissue by the steroids. Knock-down of endogenous RECK in human endometrial epithelial and stromal cells resulted in a significant increase in active MMP9 expression but not that of pro-MMP9 or MMP2. These studies demonstrate that RECK expression in the mouse uterus is steroidally regulated and that within endometrial epithelial and stromal cells, RECK regulates MMP9, but not MMP2 activity.
- 1 February 2012
- Published by Springer Nature in Endocrine
- Vol. 42 (1) , 97-106
Estrogen suppresses expression of the matrix metalloproteinase inhibitor reversion-inducing cysteine-rich protein with Kazal motifs (RECK) within the mouse uterus
RECK (reversion-inducing cysteine-rich protein with Kazal motifs) is a membrane-anchored glycoprotein which regulates MMP2 and MMP9 activity and has been proposed to play a role in embryo implantation while misexpression of RECK has been associated with a variety of carcinomas. Unfortunately, understanding on the steroidal regulation of uterine RECK is lacking. To address this gap in our knowledge, we examined steroidal regulation and cellular expression of Reck mRNA and protein within the mouse uterus in vivo. Uterine Reck mRNA and protein were decreased by estrogen, while progesterone alone had no effect. The estrogen-induced down regulation could be partially blocked by progesterone. RECK was localized primarily to luminal and glandular epithelial cells and the level of expression was regulated in a similar fashion as in whole tissue by the steroids. Knock-down of endogenous RECK in human endometrial epithelial and stromal cells resulted in a significant increase in active MMP9 expression but not that of pro-MMP9 or MMP2. These studies demonstrate that RECK expression in the mouse uterus is steroidally regulated and that within endometrial epithelial and stromal cells, RECK regulates MMP9, but not MMP2 activity.
- Open Access
- 6 October 2011
- Published by Springer Nature in BMC Complementary and Alternative Medicine
- Vol. 11 (1) , 84
Down-regulation of estrogen receptor-alpha and rearranged during transfection tyrosine kinase is associated with withaferin a-induced apoptosis in MCF-7 breast cancer cells
Withaferin A (WA), a naturally occurring withanolide, induces apoptosis in both estrogen-responsive MCF-7 and estrogen-independent MDA-MB-231 breast cancer cell lines with higher sensitivity in MCF-7 cells, but the underlying mechanisms are not well defined. The purpose of this study was to determine the anti-cancer effects of WA in MCF-7 breast cancer cells and explore alterations in estrogen receptor alpha (ERα) and its associated molecules in vitro as novel mechanisms of WA action.
- 6 October 2011
- Published by Springer Nature in BMC Complementary and Alternative Medicine
- Vol. 11 (1) , 84
Open AccessDown-regulation of estrogen receptor-alpha and rearranged during transfection tyrosine kinase is associated with withaferin a-induced apoptosis in MCF-7 breast cancer cells
Withaferin A (WA), a naturally occurring withanolide, induces apoptosis in both estrogen-responsive MCF-7 and estrogen-independent MDA-MB-231 breast cancer cell lines with higher sensitivity in MCF-7 cells, but the underlying mechanisms are not well defined. The purpose of this study was to determine the anti-cancer effects of WA in MCF-7 breast cancer cells and explore alterations in estrogen receptor alpha (ERα) and its associated molecules in vitro as novel mechanisms of WA action.